1. Home
  2. COCP vs MDRR Comparison

COCP vs MDRR Comparison

Compare COCP & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COCP
  • MDRR
  • Stock Information
  • Founded
  • COCP 2006
  • MDRR 2015
  • Country
  • COCP United States
  • MDRR United States
  • Employees
  • COCP N/A
  • MDRR N/A
  • Industry
  • COCP Biotechnology: Pharmaceutical Preparations
  • MDRR Real Estate Investment Trusts
  • Sector
  • COCP Health Care
  • MDRR Real Estate
  • Exchange
  • COCP Nasdaq
  • MDRR Nasdaq
  • Market Cap
  • COCP 15.3M
  • MDRR 15.2M
  • IPO Year
  • COCP N/A
  • MDRR 2018
  • Fundamental
  • Price
  • COCP $1.52
  • MDRR $12.25
  • Analyst Decision
  • COCP Strong Buy
  • MDRR
  • Analyst Count
  • COCP 1
  • MDRR 0
  • Target Price
  • COCP $7.00
  • MDRR N/A
  • AVG Volume (30 Days)
  • COCP 12.6K
  • MDRR 2.5K
  • Earning Date
  • COCP 05-20-2025
  • MDRR 05-16-2025
  • Dividend Yield
  • COCP N/A
  • MDRR 1.96%
  • EPS Growth
  • COCP N/A
  • MDRR N/A
  • EPS
  • COCP N/A
  • MDRR N/A
  • Revenue
  • COCP N/A
  • MDRR $9,485,128.00
  • Revenue This Year
  • COCP N/A
  • MDRR N/A
  • Revenue Next Year
  • COCP N/A
  • MDRR N/A
  • P/E Ratio
  • COCP N/A
  • MDRR N/A
  • Revenue Growth
  • COCP N/A
  • MDRR N/A
  • 52 Week Low
  • COCP $1.12
  • MDRR $10.90
  • 52 Week High
  • COCP $3.26
  • MDRR $15.00
  • Technical
  • Relative Strength Index (RSI)
  • COCP 51.20
  • MDRR 54.02
  • Support Level
  • COCP $1.36
  • MDRR $11.41
  • Resistance Level
  • COCP $1.74
  • MDRR $12.69
  • Average True Range (ATR)
  • COCP 0.18
  • MDRR 0.25
  • MACD
  • COCP 0.01
  • MDRR 0.04
  • Stochastic Oscillator
  • COCP 50.00
  • MDRR 74.71

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.

Share on Social Networks: